Mike Coyle Steps Down As iRhythm CEO; CFO Douglas Devine Will Be Interim CEO
Douglas Devine will take over as interim CEO as iRhythm tries to resolve reimbursement challenges and roll out the next generation of its Zio remote cardiac monitor with an updated artificial intelligence system.
You may also be interested in...
The company provided another update on its ongoing efforts to secure adequate Medicare reimbursement for long-term continuous cardiac monitoring.
Sean Salmon, the head of Medtronic’s diabetes business, will take over the leadership of the company’s cardiovascular business effective 1 January.
The Israeli company raised $16m to support its Augmented Respiration Technology, a novel approach for delivering oxygen directly into the venous system. The company expects to earn FDA clearance for first product by 2023.